The European Commission and the FDA have granted orphan-drug status to ReNeuron's stem cell drug ReN003 as a treatment for retinitis pigmentosa. ReNeuron plans to apply next year to conduct a Phase I/II study in the U.S. and the U.K.
U.S., EU award orphan designations to ReNeuron's stem cell eye treatment
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||